Ardelyx Inc (NASDAQ:ARDX) Stock Surges on Q3 2025 Revenue Beat and Raised Guidance

Ardelyx Inc (NASDAQ:ARDX) reported financial results for the third quarter of 2025, delivering a performance that notably exceeded analyst revenue expectations. The market responded positively to the news, with the stock posting a significant after-hours gain.

Earnings and Revenue Versus Estimates

The company's top-line performance was the standout figure from the earnings report, comfortably surpassing what analysts had projected.

• Reported Revenue: $110.3 million
• Estimated Revenue: $102.9 million
• Revenue Beat: Approximately $7.4 million

On the bottom line, the company reported a net loss of $1.0 million, or $0.00 per share. This result was an improvement over the analyst estimate for a non-GAAP EPS loss of $0.06. The company's ability to essentially break even on a per-share basis, against an expectation of a loss, contributed to the positive investor sentiment following the announcement.

Market Reaction and Price Action

The immediate market reaction to the earnings beat was decisively positive. Following the release, Ardelyx shares climbed nearly 15% in after-hours trading. This sharp upward movement indicates that investors were encouraged by the company's strong revenue growth and its progress toward profitability. The positive price action serves to reverse some of the negative momentum from the past month, during which the stock had declined approximately 7.5%.

Key Highlights from the Quarter

Beyond the headline earnings figures, the press release detailed several operational successes that underpin the financial results. The performance of the company's two commercial products was a primary driver.

• IBSRELA Growth: Revenue for IBSRELA, a treatment for irritable bowel syndrome with constipation, reached $78.2 million. This represents a staggering 92% increase compared to the same quarter in 2024 and a 20% sequential increase from the second quarter of 2025. Due to this robust performance, the company raised its full-year 2025 revenue guidance for the drug to a range of $270 to $275 million.
• XPHOZAH Progress: Revenue for XPHOZAH, a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis, was $27.4 million. This marks a 9% increase compared to the second quarter of 2025, demonstrating steady sequential growth despite a year-over-year decline attributed to changes in Medicare Part D coverage.
• Pipeline Development: Ardelyx announced the development of RDX10531, a next-generation NHE3 inhibitor. The company is preparing for an Investigational New Drug (IND) submission to the FDA in 2026, signaling a commitment to future growth.

Outlook and Analyst Expectations

The raised guidance for IBSRELA provides a clear and confident outlook for the remainder of the year. The new forecast of $270-$275 million for IBSRELA's full-year revenue sets a high bar and suggests management expects the strong growth trajectory to continue. For further detailed analysis and to track future earnings estimates for Ardelyx, more information can be found on its earnings and estimates page.

Disclaimer: This article is for informational purposes only and is not intended as investment advice. The analysis does not constitute a recommendation to buy, sell, or hold any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.